Can Allergy Shots Cure Allergies? 5 Factors That Determine Your Outcome

Yes — treatment duration is one of the strongest predictors of whether allergy shots produce durable remission. Marogna et al. (Clinical and Experimental Allergy 2010) showed that 5-year SCIT courses produced substantially more durable remission than 3-year courses, which in turn outperformed courses under 3 years. The EAACI guidelines state explicitly that at least 3 years of immunotherapy is required to achieve post-treatment benefit, with 2-year courses shown to be insufficient for lasting effects. The practical implication: patients who commit to a full 5-year course have meaningfully better cure potential than those who stop at the 3-year minimum.

Yes — children under 12 consistently show better long-term outcomes and greater disease modification from SCIT than adults. This is well-established by the PAT study and its long-term follow-ups: children who received SCIT had dramatically lower rates of developing asthma and were more likely to maintain durable allergy remission years later. The mechanisms are not entirely clear, but the earlier in life the immune system is retrained, the more flexible and lasting the immune reprogramming appears to be. This is one reason allergists often recommend starting SCIT sooner rather than later in children with moderate-to-severe allergic rhinitis.

Yes — polysensitization (allergy to multiple unrelated allergens) reduces cure potential compared to monosensitization. Des Roches et al. (JACI 1997) showed that monosensitized patients had dramatically higher rates of achieving new-sensitization-free remission than polysensitized patients. Yuan et al. confirmed that while short-term outcomes were similar between mono- and polysensitized children, two years post-treatment monosensitized patients maintained significantly more durable benefit. This is partly because multi-allergen SCIT vials may dilute the per-allergen dose below the therapeutic threshold for some components. If you have multiple sensitivities, your allergist should ensure each relevant allergen reaches adequate maintenance dosing.

Compliance is one of the most powerful predictors of long-term remission. More and Hagan (Ann Allergy Asthma Immunol 2002) found that high-compliance patients — those attending more than 90% of scheduled appointments — had approximately double the remission rate of low-compliance patients. This makes biological sense: SCIT efficacy depends on consistently reaching and sustaining the therapeutic maintenance dose. Missed injections interrupt the dose escalation process, may require restarting earlier vials, and prevent the cumulative immune retraining needed for lasting tolerance. Real-world data show only 23% of SCIT patients actually complete the recommended 3-year course, making compliance the single largest gap between trial efficacy and real-world cure rates.

Yes — environmental controls used alongside allergy shots measurably improve outcomes compared to shots alone. Nelson (JACI 2007) showed that concurrent environmental control measures — HEPA air filtration, allergen-impermeable mattress covers, regular washing of bedding, reduction of allergen sources — enhanced SCIT outcomes. The logic is straightforward: reducing ongoing allergen exposure during treatment allows the immune system to consolidate the tolerance being established by the shots, rather than being repeatedly challenged at high levels. For patients with dust mite or pet dander allergies especially, environmental controls are considered a standard complement to immunotherapy by most major allergy guidelines.

Pifferi et al. (Pediatric Allergy and Immunology 2002) found that pre-treatment skin test wheal size correlates with relative improvement from SCIT — patients with larger wheals (indicating stronger sensitization) tend to show greater relative reduction in reactivity. Lee et al. (2018) confirmed that HDM-specific IgE above 17.5 kU/L was a significant predictor of clinical remission after SCIT (OR 1.85). Milder baseline disease predicted less durable benefit (severe AR at baseline had OR 0.40 for remission), possibly because patients with milder disease have more room to be influenced by natural fluctuations and may not fully comply with treatment when symptoms seem manageable.